Giredestrant Plus Everolimus NDA Is Under FDA Review for ESR1-Mutated, ER+ Advanced Breast Cancer Read More » March 4, 2026
Iza-Bren Yields PFS and OS Benefits vs Chemo in Previously Treated, Advanced TNBC Read More » March 4, 2026
HER2DX Could Aid Chemotherapy Decision-Making in HER2+ Early-Stage Breast Cancer Read More » November 6, 2025
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer Read More » October 16, 2025
ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC Read More » July 28, 2025
Cellular senescence predicts breast cancer risk from benign breast disease biopsy images Read More » March 17, 2025
